Sebastien Groyer

Mdxhealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

At BALYO, we believe that pallet movements in warehouses, DC and manufacturing sites should be left to fully autonomous robots. Afterall, humans around the world deserve enriching, creative jobs. To execute this ambition, BALYO transforms standard forklifts into intelligent robots thanks to its breakthrough Driven by Balyo™technology. Our leading geo guidance navigation system enables robots to locate their position and navigate autonomously inside buildings - without the need for any additional infrastructure. To accelerate the material handling market conversion to autonomy, BALYO has entered into two global partnerships with KION (Linde Material Handlings parent company) and Hyster-Yale Group. A full range of globally available robots has been developed for virtually all traditional warehousing applications: Tractor, Pallet, Stackers, Reach and VNA-robots. BALYO and its subsidiaries in Boston and Singapore serve clients in the Americas, Europe and Asia-Pacific. The company has been listed on EURONEXT since 2017 and its sales revenue reached €21.7 million in 2020. For more information, visit https://www.balyo.com.

Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com

Global Bioenergies convertit des ressources végétales en composés utilisés en cosmétique ainsi que dans les domaines de l’énergie et des matériaux. Après avoir lancé en 2021 la première marque de maquillage longue-tenue et naturelle LAST®, Global Bioenergies commercialise à présent l’Isonaturane® 12, son ingrédient-clé, aux grands acteurs de la cosmétique afin d’améliorer la naturalité de leurs formulations et leur empreinte environnementale. A terme, Global Bioenergies porte la perspective de réduire les émissions de CO2 des transports aériens et routiers pour contribuer ainsi à limiter le réchauffement climatique. Global Bioenergies est cotée sur Euronext Growth à Paris (FR0011052257 – ALGBE). Global Bioenergies converts plant-derived resources into compounds used in the cosmetics industry, as well as the energy and materials sectors. After launching the first long-lasting and natural make-up brand LAST® in 2021, Global Bioenergies is now marketing Isonaturane® 12, its key ingredient, to major cosmetics companies to improve the naturalness of their formulas whilst improving their carbon footprint. In the long run, Global Bioenergies is also aiming at cutting CO2 emissions in the aviation and road sector and thereby curb global warming. Global Bioenergies is listed on Euronext Growth Paris (FR0011052257 - ALGBE)

MLstate develops state-of-the-art web exchange platforms -- enabling to safely manage emails and file sharing within organizations. The solutions are built with the Opa technology, pioneered by MLstate, which was a finalist of GigaOM Structure 2012 and the recipient of the French Ministry of Research innovation award. MLstate was acquired by Wallix in 2016.

CDC Entreprises is a portfolio management company approved by the AMF (Autorité des Marchés Financiers, the French Financial Markets Authority), and a wholly-owned subsidiary of the French Caisse des Dépôts. CDC Entreprises is in charge of the group’s public interest activities in the field of private equity investments dedicated to SMEs. CDC Entreprises is a direct investor and a funds-of-funds investor in SMEs, on a national and regional level, covering all private equity segments from technology seed funding to small-cap buy-outs. The largest investor in the funds managed by CDC Entreprises is the Caisse des Dépôts group (through, inter alia, the FSI). Other investors include public and private financial institutions and corporate investors. The mission of CDC Entreprises is to encourage the emergence of companies experiencing sustainable growth by strengthening their equity.

Vacuum Cancer is a European Healthcare startup developing a new treatment against advanced solid cancer.

Praxy.ai, founded by doctors and AI engineers, has developed an AI suite for healthcare professionals, our products free up their time, while improving the completeness and precision of therapeutic patient monitoring. Our first product on the market is a multi-channel solution (physical consultation, telephone, videoconferencing, mobility) which automatically generates consultation reports and updates patients medical records.

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. #BetterMedicineForAll #ImpactHealth #GlobalHealth #ControlledRelease #CreativeThinking #InnovationForward #Science

Mdxhealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.